Anvisa Approves First Version of Wegovy Slimming Pen Tablets
7 Articles
7 Articles
The National Agency for Health Surveillance (Anvisa) approved, on Wednesday, a tablet version of the medicine Wegovy, of the Danish pharmaceutical company Novo Nordisk, for the treatment of obesity. The drug, which has as its active principle the semiglutide, is the first oral version of a medicine of the class known as "sagreing pens" to receive the endorsement in Brazil. What does it mean to walk with your hands behind your back, according to …
Oral version of semaglutide has a daily maintenance dose of 25 mg and should reach the pharmacies in the next quarter, according to the manufacturer
The authorisation envisages the first presentation in tablets of the medicinal product, until then available in Brazil only in the injectable form
Oral drug based on semaglutide should reach Brazilian pharmacies in the first half of 2027
The treatment provides for a progressive dosing step, starting at 1.5 mg; check for more information The post Anvisa approves Wegovy in tablets for the treatment of obesity; medicine with semaglutide was sold only in injectable version apareceu primeiro em ND More
The first "sweetening pen" as a tablet was approved by the National Agency for Health Surveillance (Anvisa), on Wednesday, 4. The medicine is a new version of Wegovy, of the Danish pharmaceutical company Novo Nordisk and, like the original one, has as an active principle Semaglutide.Like the injectable version, the drug also acts in the regulation of appetite and food intake, promoting reduction of body weight and improvement of metabolic parame…
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
